PSUR Timelines and Regional Requirements

Published on 22/12/2025

Understanding PSUR Timelines and Regional Regulatory Requirements

The Periodic Safety Update Report (PSUR) is a fundamental pharmacovigilance tool used globally to monitor and evaluate the safety profile of pharmaceutical products. While its core structure is standardized by ICH E2C(R2), the timelines and regulatory requirements for PSUR submission vary significantly across different regions. This article outlines these timelines, differences in expectations, and how companies can maintain compliance with multiple health authorities.

Table of Contents

What is a PSUR and Why Do Timelines Matter?

A PSUR is a cumulative safety report submitted at predefined intervals to summarize adverse events (AEs), benefit-risk assessments, and new safety signals. Timely submission is essential for:

Demonstrating ongoing pharmacovigilance compliance
Informing regulatory decisions on labeling or product safety
Maintaining marketing authorization in various jurisdictions
Preventing compliance risks or delays in clinical development

Each regulatory authority prescribes its own frequency and deadlines for PSUR submissions, making global alignment complex yet essential.

ICH Guidelines on PSUR Frequency

Under ICH E2C(R2), the general guideline for PSUR periodicity for newly authorized medicinal products is:

Every 6 months for the first 2 years post-marketing
Annually for the next 3 years
Every 3 years thereafter (unless otherwise specified)

These are considered default timelines unless superseded by regional requirements or inclusion in the EU Reference

Date (EURD) list.

European Union (EMA) Requirements

The EMA mandates PSUR submissions in the form of Periodic Benefit-Risk Evaluation Reports (PBRERs). The timelines are based on the EURD list, which sets harmonized submission dates for products with the same active ingredient.

Key facts:

Submission via the EMA’s EVWeb portal
PBRER format mandatory since July 2012
Centralized database tracking PSUR frequency and harmonization

United States (USFDA) Requirements

In the U.S., PSUR-like reports are referred to as PADERs (Periodic Adverse Drug Experience Reports) or NDA annual reports. The PSUR format is accepted for harmonization with ICH-compliant regions but must be supplemented with specific FDA requirements.

Quarterly for the first 3 years
Annually thereafter
Submitted to the FDA’s Electronic Submission Gateway (ESG)

India (CDSCO) Requirements

The CDSCO mandates PSURs during the clinical trial and early post-marketing phases.

Every 6 months for the first 2 years after marketing approval
Annually for the next 2 years
Format aligned with ICH E2C(R2), but national templates may apply
Submission via the Sugam online portal

Other Regional Requirements

Japan (PMDA)

Uses a hybrid of PBRER and its own Periodic Infection Safety Reports (PISR)
Submission interval: defined case-by-case

Canada (Health Canada)

Follows ICH E2C(R2)
Submission through eCTD format using Health Canada portal

Australia (TGA)

Requires PBRERs for high-risk products
May align with EMA’s EURD submission schedule
Submission via TGA Business Services (TBS)

South Africa (SAHPRA)

Follows ICH E2C(R2)
Schedule based on risk profile and initial approval timelines
Online submission via SAHPRA

Brazil (ANVISA)

Uses PBRER format for all PSUR submissions
Timeframes harmonized with EMA unless otherwise stated
Electronic submission via Datavisa

Global Harmonization Challenges

Pharma companies operating in multiple regions must navigate:

Different submission platforms and formats
Multiple Data Lock Points (DLPs)
Varying expectations for benefit-risk analysis
Synchronization between centralized and decentralized procedures

Using a centralized safety data platform and following GMP documentation best practices is critical for managing timelines effectively.

Best Practices to Ensure Timely PSUR Submissions

Maintain a PSUR submission calendar across all jurisdictions
Align internal DLPs with regulatory EURD timelines
Automate reminder systems for approaching deadlines
Coordinate PSUR planning with regulatory intelligence teams
Conduct dry-run submissions for system validations

Using validated systems for tracking submission readiness can also reduce errors and missed deadlines.

Tools for Tracking PSUR Timelines

PSUR Dashboard: Gantt-style visual tracking
EURD Lookup Tool from EMA
Global PV Submission Calendar (integrated into RIM systems)
Excel trackers with conditional alerts

Where possible, synchronize PSUR and PBRER schedules across regions to reduce duplicate efforts.

Conclusion

PSUR timelines and regional submission requirements are a cornerstone of global pharmacovigilance strategy. Understanding and mapping these variations is essential for regulatory compliance and operational efficiency. By using harmonized ICH guidelines as the foundation and layering regional specifics, pharma companies can maintain timely and high-quality safety submissions worldwide. Investing in robust planning systems, internal SOPs, and cross-functional coordination ensures that PSUR obligations are met without disruption to development timelines or post-marketing lifecycle management.